Multiple Manufacturers


ASP | WAC | AWP at the HCPCS Unit


Multiple Manufacturers

Panzyga HCPCS:


HCPCS Code Descriptor:

Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg


J Code

Panzyga NDCs:

00069-1109-02, 68982-0822-01, 68982-0822-02, 00069-1011-02, 00069-1558-02, 68982-0822-06, 00069-1415-02, 68982-0822-05, 00069-1312-02, 68982-0822-04, 68982-0822-03, 00069-1224-02

Primary Type:


Generic/Specialty Status:


Package Type:


Route of Administration:


Panzyga CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Panzyga:

PANZYGA is a medication manufactured by multiple manufacturers and aligned to the J Code: J1576. PANZYGA is administered via the intravenous route of administration.

Panzyga is an immunoglobulin medication that works by using human blood containing high levels of antibodies. Panzyga can be used to aid the patient’s immunes system and can also be used to treat certain neurological disorders. This medication is manufactured by Octapharma and Pfizer. The J code: J1576 was aligned to this medication in July of 2023 under the 505(B)(2) pathway. The NDCs aligned to this code were previously aligned to the miscellaneous code for Panzyga: J1599. Patient assistance programs for this medication can be found through Panzyga’s website.


J1576 Added Date:

July 1, 2023

J1576 Effective Date:

July 1, 2023

J1576 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Panzyga billing and coding information.
Panzyga patient assistance information can be found through MyPanzyga at the URL:
PANZYGA prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for PANZYGA. Please check back in a few weeks. Drug Alert: